Intrepid Financial Planning Group LLC Sells 450 Shares of Amdocs Limited (NASDAQ:DOX)

Intrepid Financial Planning Group LLC decreased its holdings in Amdocs Limited (NASDAQ:DOX) by 6.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,780 shares of the technology company’s stock after selling 450 shares during the quarter. Intrepid Financial Planning Group LLC’s holdings in Amdocs were worth $593,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Pzena Investment Management LLC increased its stake in Amdocs by 33.2% in the 2nd quarter. Pzena Investment Management LLC now owns 5,667,603 shares of the technology company’s stock valued at $447,287,000 after buying an additional 1,412,826 shares during the last quarter. LSV Asset Management increased its stake in Amdocs by 7.9% in the 2nd quarter. LSV Asset Management now owns 3,207,155 shares of the technology company’s stock valued at $253,109,000 after buying an additional 234,096 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Amdocs by 36.6% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,175,790 shares of the technology company’s stock valued at $277,818,000 after buying an additional 851,022 shares during the last quarter. Brandes Investment Partners LP increased its stake in Amdocs by 31.1% in the 2nd quarter. Brandes Investment Partners LP now owns 2,260,811 shares of the technology company’s stock valued at $178,335,000 after buying an additional 536,359 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Amdocs by 39.5% in the 1st quarter. Vanguard Group Inc. now owns 2,033,536 shares of the technology company’s stock valued at $183,771,000 after buying an additional 576,168 shares during the last quarter. Institutional investors own 92.02% of the company’s stock.

Analysts Set New Price Targets

DOX has been the subject of several analyst reports. StockNews.com upgraded shares of Amdocs from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 25th. Stifel Nicolaus began coverage on shares of Amdocs in a research note on Wednesday, October 2nd. They set a “buy” rating and a $100.00 price target for the company. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Amdocs presently has a consensus rating of “Buy” and an average price target of $102.00.

Amdocs Trading Up 0.7 %

Shares of DOX stock opened at $92.86 on Tuesday. The company has a 50 day moving average of $88.04 and a 200-day moving average of $83.86. The company has a quick ratio of 1.24, a current ratio of 1.24 and a debt-to-equity ratio of 0.21. Amdocs Limited has a 12-month low of $74.41 and a 12-month high of $94.04. The firm has a market cap of $10.91 billion, a P/E ratio of 21.40, a PEG ratio of 1.49 and a beta of 0.74.

Amdocs Company Profile

Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.